No abstract

(1) Background: Although there are extensive data on admission co-variates and outcomes of persons with coronavirus infectious disease-2019 (COVID-19) at diverse geographic sites, there are few, if any, subject-level comparisons between sites in regions and countries. We investigated differences in hospital admission co-variates and outcomes of hospitalized people with COVID-19 between Wuhan City, China and the New York City region, USA. (2) Methods: We retrospectively analyzed clinical data on 1859 hospitalized subjects with COVID-19 in Wuhan City, China, from 20 January to 4 April 2020. Data on 5700 hospitalized subjects with COVID-19 in the New York City region, USA, from 1 March to 4 April 2020 were extracted from an article by Richardson et al. Hospital admission co-variates (epidemiological, demographic, and laboratory co-variates) and outcomes (rate of intensive care unit [ICU] admission, invasive mechanical ventilation [IMV], major organ failure and death, and length of hospital stay) were compared between the cohorts. (3) Results: Wuhan subjects were younger, more likely female, less likely to have co-morbidities and fever, more likely to have a blood lymphocyte concentration > 1 × 109/L, and less likely to have abnormal liver and cardiac function tests compared with New York subjects. There were outcomes data on all Wuhan subjects and 2634 New York subjects. Wuhan subjects had higher blood nadir median lymphocyte concentrations and longer hospitalizations, and were less likely to receive IMV, ICU hospitalization, and interventions for kidney failure. Amongst subjects not receiving IMV, those in Wuhan were less likely to die compared with New York subjects. In contrast, risk of death was similar in subjects receiving IMV at both sites. (4) Conclusions: We found different hospital admission co-variates and outcomes between hospitalized persons with COVID-19 between Wuhan City and the New York region, which should be useful developing a comprehensive global understanding of the SARS-CoV-2 pandemic and COVID-19.

BackgroundDespite the incorporation of various clinical and molecular criteria in the diagnosis and prognosis prediction of low-grade glioma, individual variation and risk stratification have not been completely explored. Necroptosis is considered closely related to different types of cancers, including low-grade gliomas. In this study, we obtained the necroptosis genes from the Kyoto Encyclopedia of Genes and Genomes website, extracted necroptosis genes from The Cancer Genome Atlas, and established a necroptosis-related gene signature (NECSig) through hazard analyses. Then we established a prognostic risk model consisting of four NECSig (BID, H2AFY2, MAPK9, and TNFRSF10B).ResultBased on the model, the high-risk group is significantly associated with poorer overall survival. The accuracy of this model is further supported by the receiver operating characteristic curve. Then, we constructed a prognostic nomogram combining NECSig and clinical features, which shows good predictive power for stratification of survival risk. We discovered variations in the kind of immune infiltration, immune cells, and functions between the high-risk and low-risk groups using this risk model. We also showed that drug therapy is more sensitive in high-risk populations.ConclusionThe results revealed a prognostic indicator of NECSig, which may provide information for immunological research and treatment of low-grade gliomas.